Biotechnology company BRAIN and natural product specialist AnalytiCon Discovery GmbH have formed a unique partnership in the rapidly growing health and nutrition sector. Through its acquisition of the majority of AnalytiCon shares, BRAIN has become a leading international company network with unique worldwide access to an extensive range of natural products, microorganisms, plants, gene libraries and the associated technologies required for identification, development and production of products based on natural substances for consumers and business partners.
Through the establishment of this alliance, many years of research and development in the field of natural products and natural extracts are combined with extensive technology platforms for the detection of novel biological activity and subsequent structure-efficacy relation-ships. Both companies have more than 20 years of research and development experience in an industrial environment and have al-ready worked together successfully on a variety of industrial projects for about 10 years.
The AnalytiCon company shares were sold to BRAIN by previous long-term private shareholders and the investors Sobera Capital GmbH and KBB Kapitalgesellschaft mbH. Shareholders now are solely BRAIN and the management as well as some key personnel of AnalytiCon. Further details of the transaction have not been disclosed.
The newly created network combines the complementary disciplines of biology and natural product chemistry. The company alliance also synergistically enhances access to natural resources (often referred to as "nature's toolbox") as, in addition to the multitude of highly di-verse microorganisms, an extensive range of secondary metabolisms of plants that are a source of natural products and innovative production systems are made available. BRAIN and AnalytiCon aim to work alongside one another to find and implement the most eco-nomic solutions to emerging technical issues.
The intensification of these joint activities is of particular interest in the health and nutrition sector, where "all natural" concepts combined with proven biological effects are increasingly important for both market players and end users.
"AnalytiCon has been working intensively on its Drug Discovery units within the pharmaceutical industry for several years. This alliance makes it possible to further bridge the gap between the pharmaceuti-cal, food and cosmetics industries," explains Dr. Lutz Müller-Kuhrt, CEO of AnalytiCon. "Through this new alliance with its long-standing partner BRAIN, the company will be strengthened further but will continue to operate independently on the market."
"The synergy between the disciplines of biotechnology and natural product chemistry established in the alliance brings the two partners to a key position for fully integrated drug development. This is seen internationally as being very unique," says Dr. Holger Zinke, CEO of BRAIN AG, of the importance of the newly formed partnership. "The alliance combines the development of novel screening tests with direct access to an infinite source of natural products, therefore offer-ing the opportunity to additionally optimise certain natural product candidates through chemical synthesis, in terms of properties such as stability, solubility or efficiency."
This will allow the two companies to strengthen their own develop-ments for the consumer market in the future. With this in mind, the companies have worked together since February 2013 as part of the strategic alliance NatLife 2020, which has allowed natural nutraceuti-cals and cosmeceuticals to be identified, developed and produced with the aim of improving formulations in the food and cosmetics market.
The work of the 22 strategic alliance partners is planned to last 9 years and is supported by the Federal Ministry of Education and Re-search. The total funding amount is 30 million Euros. Intermediate- and long-term "Natural Product" businesses will therefore be built up, meaning both alliance partners can move forward on the value chain together.
About AnalytiCon Discovery
AnalytiCon Discovery GmbH operates internationally and is the global market leader in the field of natural product (NP) compound libraries featuring fully elucidated structures. With its 60 employees at Potsdam Biotech Campus, it offers services for every phase of the supply chain for NP-based drug discovery and development. The company offers the full range of services for the accelerated development of NP-based lead structures, from procurement of raw biomaterials to fermentation, isolation and high-throughput structure elucidation all the way to NP-focused medicinal chemistry. The innovative technology concept employed by AnalytiCon has led to top-class contracts with companies from the pharmaceutical, food and cosmetics industries in Europe, USA and Japan. Furthermore, AnalytiCon has established the BIOS concept (Biology Oriented Synthesis), a technology for developing and producing focused combinatorial compound libraries based on rare NP core structures that contain bioactive structural elements (Nat-DiverseTM). In the process, the company has gained access to currently over 15% of all known natural products worldwide as well as to thousands of yet unpublished structures
www.ac-discovery.com
Through the establishment of this alliance, many years of research and development in the field of natural products and natural extracts are combined with extensive technology platforms for the detection of novel biological activity and subsequent structure-efficacy relation-ships. Both companies have more than 20 years of research and development experience in an industrial environment and have al-ready worked together successfully on a variety of industrial projects for about 10 years.
The AnalytiCon company shares were sold to BRAIN by previous long-term private shareholders and the investors Sobera Capital GmbH and KBB Kapitalgesellschaft mbH. Shareholders now are solely BRAIN and the management as well as some key personnel of AnalytiCon. Further details of the transaction have not been disclosed.
The newly created network combines the complementary disciplines of biology and natural product chemistry. The company alliance also synergistically enhances access to natural resources (often referred to as "nature's toolbox") as, in addition to the multitude of highly di-verse microorganisms, an extensive range of secondary metabolisms of plants that are a source of natural products and innovative production systems are made available. BRAIN and AnalytiCon aim to work alongside one another to find and implement the most eco-nomic solutions to emerging technical issues.
The intensification of these joint activities is of particular interest in the health and nutrition sector, where "all natural" concepts combined with proven biological effects are increasingly important for both market players and end users.
"AnalytiCon has been working intensively on its Drug Discovery units within the pharmaceutical industry for several years. This alliance makes it possible to further bridge the gap between the pharmaceuti-cal, food and cosmetics industries," explains Dr. Lutz Müller-Kuhrt, CEO of AnalytiCon. "Through this new alliance with its long-standing partner BRAIN, the company will be strengthened further but will continue to operate independently on the market."
"The synergy between the disciplines of biotechnology and natural product chemistry established in the alliance brings the two partners to a key position for fully integrated drug development. This is seen internationally as being very unique," says Dr. Holger Zinke, CEO of BRAIN AG, of the importance of the newly formed partnership. "The alliance combines the development of novel screening tests with direct access to an infinite source of natural products, therefore offer-ing the opportunity to additionally optimise certain natural product candidates through chemical synthesis, in terms of properties such as stability, solubility or efficiency."
This will allow the two companies to strengthen their own develop-ments for the consumer market in the future. With this in mind, the companies have worked together since February 2013 as part of the strategic alliance NatLife 2020, which has allowed natural nutraceuti-cals and cosmeceuticals to be identified, developed and produced with the aim of improving formulations in the food and cosmetics market.
The work of the 22 strategic alliance partners is planned to last 9 years and is supported by the Federal Ministry of Education and Re-search. The total funding amount is 30 million Euros. Intermediate- and long-term "Natural Product" businesses will therefore be built up, meaning both alliance partners can move forward on the value chain together.
About AnalytiCon Discovery
AnalytiCon Discovery GmbH operates internationally and is the global market leader in the field of natural product (NP) compound libraries featuring fully elucidated structures. With its 60 employees at Potsdam Biotech Campus, it offers services for every phase of the supply chain for NP-based drug discovery and development. The company offers the full range of services for the accelerated development of NP-based lead structures, from procurement of raw biomaterials to fermentation, isolation and high-throughput structure elucidation all the way to NP-focused medicinal chemistry. The innovative technology concept employed by AnalytiCon has led to top-class contracts with companies from the pharmaceutical, food and cosmetics industries in Europe, USA and Japan. Furthermore, AnalytiCon has established the BIOS concept (Biology Oriented Synthesis), a technology for developing and producing focused combinatorial compound libraries based on rare NP core structures that contain bioactive structural elements (Nat-DiverseTM). In the process, the company has gained access to currently over 15% of all known natural products worldwide as well as to thousands of yet unpublished structures
www.ac-discovery.com
